| Literature DB >> 26703540 |
Xing-Dong Wu1,2,3, Hua-Guo Chen4,5, Xin Zhou6,7,8, Ya Huang9,10,11, En-Ming Hu12,13, Zheng-Meng Jiang14,15, Chao Zhao16,17, Xiao-Jian Gong18,19, Qing-Fang Deng20,21.
Abstract
This work investigated the spectrum-effect relationships between high performance liquid chromatography (HPLC) fingerprints and the anti-benign prostatic hyperplasia activities of aqueous extracts from Saxifraga stolonifera. The fingerprints of S. stolonifera from various sources were established by HPLC and evaluated by similarity analysis (SA), hierarchical clustering analysis (HCA) and principal component analysis (PCA). Nine samples were obtained from these 24 batches of different origins, according to the results of SA, HCA and the common chromatographic peaks area. A testosterone-induced mouse model of benign prostatic hyperplasia (BPH) was used to establish the anti-benign prostatic hyperplasia activities of these nine S. stolonifera samples. The model was evaluated by analyzing prostatic index (PI), serum acid phosphatase (ACP) activity, concentrations of serum dihydrotestosterone (DHT), prostatic acid phosphatase (PACP) and type II 5α-reductase (SRD5A2). The spectrum-effect relationships between HPLC fingerprints and anti-benign prostatic hyperplasia activities were investigated using Grey Correlation Analysis (GRA) and partial least squares regression (PLSR). The results showed that a close correlation existed between the fingerprints and anti-benign prostatic hyperplasia activities, and peak 14 (chlorogenic acid), peak 17 (quercetin 5-O-β-d-glucopyranoside) and peak 18 (quercetin 3-O-β-l-rhamno-pyranoside) in the HPLC fingerprints might be the main active components against anti-benign prostatic hyperplasia. This work provides a general model for the study of spectrum-effect relationships of S. stolonifera by combing HPLC fingerprints with a testosterone-induced mouse model of BPH, which can be employed to discover the principle components of anti-benign prostatic hyperplasia bioactivity.Entities:
Keywords: HPLC fingerprints; Saxifraga stolonifera; anti-benign prostatic hyperplasia activities; chemometrics; spectrum–effect relationships
Mesh:
Substances:
Year: 2015 PMID: 26703540 PMCID: PMC6332099 DOI: 10.3390/molecules201219882
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1(a) The high performance liquid chromatography (HPLC) fingerprints of aqueous extracts of S. stolonifera from various sources; (b) The reference chromatogram was generated from the fingerprints of the 24 batches of S. stolonifera samples by using the Similarity Evaluation System for Chromatographic Fingerprint of traditional Chinese medicines (TCM) using the median method.
Collected information and similarity of the samples.
| Sample No. | Sources | Acquisition Time | Similarity | Sample No. | Sources | Acquisition Time | Similarity |
|---|---|---|---|---|---|---|---|
| Haozhou city, Medicine Market, Anhui | May, 2014 | 0.984 | Kaiyang county, Medicine Market, Guizhou | May, 2014 | 0.949 | ||
| Baiyun town, Guizhou | April, 2014 | 0.978 | Censong town, Guizhou | April, 2014 | 0.979 | ||
| Qingchang town, Guizhou | June, 2014 | 0.027 | Majiangxiasi town, Guizhou | October, 2012 | 0.981 | ||
| Yanxia town, Guizhou | July, 2014 | 0.972 | Dujiangyan city Medicine Market, Sichuan | April, 2014 | 0.758 | ||
| Guilin city, Medicine Market, Guangxi | May, 2014 | 0.983 | Benzhuang town, Guizhou | March, 2014 | 0.956 | ||
| Qingping, Medicine Market, Guangdong | March, 2014 | 0.972 | Qitan town, Guizhou | April, 2014 | 0.990 | ||
| Huaguoyuan, Medicine Market, Guizhou | May, 2014 | 0.979 | Shidong town, Guizhou | March, 2014 | 0.983 | ||
| Dongfeng town, Guizhou | July, 2014 | 0.599 | Zhenfeng county, Medicine Market, Guizhou | April, 2014 | 0.986 | ||
| Shuitian town, Guizhou | March, 2014 | 0.935 | Liutong town, Guizhou | March, 2014 | 0.942 | ||
| Guizhou, Botanical Garden, Guizhou | April, 2014 | 0.973 | Liutun town, Guizhou | July, 2014 | 0.981 | ||
| Baoding city, Medicine Market, Hebei | May, 2014 | 0.981 | Zhazuo town, Guizhou | July, 2014 | 0.941 | ||
| Gaopo town, Guizhou | March, 2014 | 0.970 | Banqiao town, Guizhou | June, 2014 | 0.967 |
Figure 2Hierarchical clustering analysis of S. stolonifera samples. The hierarchical clustering analysis (HCA) of samples 1–24 was performed using SPSS statistics software (SPSS for Windows 20.0, SPSS Inc., New York, NY, USA). A method called Between-Groups Linkage was applied. І and II represent cluster I and cluster II, respectively. A and B represent subgroup A and subgroup B, respectively.
Total Variance Explained.
| Component | Initial Eigenvalues | Extraction Sums of Squared Loadings | |||
|---|---|---|---|---|---|
| Total | % of Variance | Cumulative % | Total | % of Variance | |
| 1 | 4.324 | 24.022 | 24.022 | 4.324 | 24.022 |
| 2 | 3.075 | 17.085 | 41.107 | 3.075 | 17.085 |
| 3 | 2.741 | 15.228 | 56.335 | 2.741 | 15.228 |
| 4 | 2.192 | 12.179 | 68.513 | 2.192 | 12.179 |
| 5 | 1.569 | 8.716 | 77.230 | 1.569 | 8.716 |
| 6 | 0.947 | 5.261 | 82.490 | 0.947 | 5.261 |
| 7 | 0.816 | 4.533 | 87.023 | 0.816 | 4.533 |
| 8 | 0.699 | 3.882 | 90.906 | 0.699 | 3.882 |
| 9 | 0.407 | 2.264 | 93.169 | 0.407 | 2.264 |
| 10 | 0.346 | 1.922 | 95.092 | 0.346 | 1.922 |
| 11 | 0.267 | 1.485 | 96.577 | 0.267 | 1.485 |
| 12 | 0.221 | 1.231 | 97.807 | 0.221 | 1.231 |
| 13 | 0.159 | 0.882 | 98.689 | 0.159 | 0.882 |
| 14 | 0.099 | 0.552 | 99.241 | 0.099 | 0.552 |
| 15 | 0.081 | 0.451 | 99.692 | 0.081 | 0.451 |
| 16 | 0.040 | 0.220 | 99.913 | 0.040 | 0.220 |
| 17 | 0.013 | 0.071 | 99.984 | 0.013 | 0.071 |
| 18 | 0.003 | 0.016 | 100.000 | 0.003 | 0.016 |
Effect of aqueous extracts of S. stolonifera on the serum acid phosphatase (ACP) activity, prostate index (PI), and the concentration of serum dihydrotestosterone (DHT), prostatic acid phosphatase (PACP) and SRD5A2 in a castration and testosterone-induced mice model of benign prostatic hyperplasia (BPH).
| Groups | Prostatic Index (mg/100 g Body Weight) | Serum DHT Concentration (nmol/L) | Serum ACP Activity (IU/L) | Serum PACP Concentration (ng/L) | Serum SRD5A2 Concentration (pg/L) |
|---|---|---|---|---|---|
| control group | 36.42 ± 2.36 ## | 130.50 ± 15.41 ## | 47.89 ± 5.90 ## | 647.85 ± 54.63 ## | 78.23 ± 9.26 ## |
| BPH model control group | 51.52 ± 5.56 | 187.54 ± 29.75 | 69.79 ± 8.45 | 816.66 ± 60.85 | 125.23 ± 9.69 |
| Finasteride control group | 35.15 ± 5.33 ## | 126.47 ± 15.42 ## | 46.63 ± 8.49 ## | 698.06 ± 32.38 ## | 90.72 ± 9.54 ## |
| QKPT control group | 36.11 ± 3.46 ## | 128.43 ± 18.00 ## | 50.60 ± 7.84 ## | 675.98 ± 55.81 ## | 89.86 ± 12.60 ## |
| group A | 37.47 ± 4.67 ## | 127.02 ± 14.80 ## | 50.23 ± 4.89 ## | 708.86 ± 40.00 ## | 101.04 ± 13.99 ## |
| group B | 37.22 ± 7.34 ## | 133.97 ± 7.79 ## | 54.23 ± 5.91 ## | 750.58 ± 47.51 # | 105.10 ± 6.61 # |
| group C | 38.57 ± 5.84 ## | 153.06 ± 28.35 ## | 55.18 ± 5.39 ## | 878.04 ± 50.05 # | 106.87 ± 19.10 # |
| group D | 38.09 ± 6.07 ## | 125.02 ± 13.57 ## | 48.76 ± 5.46 ## | 755.04 ± 42.58 # | 99.89 ± 8.35 ## |
| group E | 38.10 ± 5.03 ## | 143.39 ± 17.74 ## | 48.95 ± 6.24 ## | 755.50 ± 51.82 # | 102.15 ± 11.32 ## |
| group F | 41.07 ± 5.37 ## | 151.88 ± 22.64 ## | 48.92 ± 6.28 ## | 776.68 ± 68.20 | 106.97 ± 15.05 # |
| group G | 41.57 ± 7.43 # | 129.50 ± 8.10 ## | 48.46 ± 6.57 ## | 769.71 ± 98.94 | 108.68 ± 9.03 # |
| group H | 36.53 ± 5.32 ## | 162.25 ± 15.47 # | 52.14 ± 7.95 ## | 792.84 ± 36.84 | 109.76 ± 10.09 |
| group I | 39.70 ± 5.24 ## | 165.30 ± 19.39 # | 53.78 ± 8.57 ## | 746.88 ± 19.32 ## | 114.82 ± 7.74 |
Values are mean ± SD, n = 12/group; PI: prostatic index; DHT: dihydrotestosterone; ACP: acid phosphatase; PACP: prostatic acid phosphatase; SRD5A2: type 2,5-alpha-reductase. # p < 0.05; ## p < 0.01 vs. BPH model control group, one way ANOVA and Dunnett’s multiple comparisons t.
The calculated grey relational coefficient and grey relational grade for 18 comparability sequences and their order.
| NO. | Y1 | Y2 | Y3 | Y4 | Y5 | Average | Order |
|---|---|---|---|---|---|---|---|
| A1 | 0.573 | 0.651 | 0.584 | 0.641 | 0.573 | 0.604 | 9 |
| A2 | 0.522 | 0.525 | 0.496 | 0.620 | 0.522 | 0.537 | 17 |
| A3 | 0.557 | 0.630 | 0.536 | 0.640 | 0.557 | 0.584 | 13 |
| A4 | 0.626 | 0.698 | 0.595 | 0.673 | 0.626 | 0.644 | 5 |
| A5 | 0.566 | 0.621 | 0.539 | 0.659 | 0.566 | 0.590 | 12 |
| A6 | 0.532 | 0.583 | 0.534 | 0.641 | 0.532 | 0.564 | 15 |
| A7 | 0.567 | 0.638 | 0.564 | 0.644 | 0.567 | 0.596 | 11 |
| A8 | 0.525 | 0.587 | 0.514 | 0.608 | 0.525 | 0.552 | 16 |
| A9 | 0.619 | 0.615 | 0.650 | 0.636 | 0.619 | 0.628 | 8 |
| A10 | 0.588 | 0.644 | 0.546 | 0.655 | 0.588 | 0.604 | 9 |
| A11 | 0.579 | 0.581 | 0.548 | 0.702 | 0.579 | 0.598 | 10 |
| A12 | 0.555 | 0.622 | 0.538 | 0.646 | 0.555 | 0.583 | 14 |
| A13 | 0.623 | 0.641 | 0.611 | 0.716 | 0.623 | 0.643 | 6 |
| A14 | 0.724 | 0.733 | 0.669 | 0.774 | 0.724 | 0.725 | 2 |
| A15 | 0.631 | 0.622 | 0.661 | 0.621 | 0.631 | 0.633 | 7 |
| A16 | 0.656 | 0.635 | 0.650 | 0.656 | 0.656 | 0.651 | 4 |
| A17 | 0.736 | 0.658 | 0.704 | 0.677 | 0.736 | 0.702 | 3 |
| A18 | 0.869 | 0.744 | 0.838 | 0.819 | 0.869 | 0.828 | 1 |
Figure 3Regression coefficient figure of the 18 compounds and the five indicates about benign prostatic hyperplasia. (a) is the regression coefficient figure of PI and the 18 compounds; (b) is the regression coefficient figure of DHT and the 18 compounds; (c) is the regression coefficient figure of ACP and the 18 compounds; (d) is the regression coefficient figure of PACP and the 18 compounds; (e) is the regression coefficient figure of SRD5A2 and the 18 compounds.